Movement Alert｜Thermo Fisher Scientific Falls 3.1% in Regular Trading, Multiple Analyst Downgrades Weigh on Sentiment Amid Sector Weakness

Market Focus06-18

On June 18, Thermo Fisher Scientific declined 3.1% in regular trading, trading at $459.11/share, with turnover of $487 million.

On the news front, multiple institutional rating actions continue to pressure the stock. Piper Sandler initiated coverage with a Neutral rating and a $510 price target, while HSBC downgraded the stock from Buy to Hold, slashing its target price from $670 to $540. These cautious stances from major brokerages have sustained downward pressure on share performance. The current price remains well below the analyst consensus target of $602.50.

The broader Life Sciences Tools & Services sector is also under significant pressure. Among sector peers, IQVIA fell 4.48%, Adaptive Biotechnologies declined 4.06%, Danaher dropped 2.51%, Tempus AI slid 2.20%, and Waters lost 1.09%, reflecting a broad-based sector selloff amplifying the downside momentum.

Thermo Fisher Scientific, founded in 1956 and headquartered in Waltham, Massachusetts, is a global leader in scientific services, providing life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products through brands including Thermo Scientific, Applied Biosystems, and Invitrogen.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment